Expert Interview
Evaluating Merck's Winrevair (Sotatercept) for Early-Stage Pulmonary Arterial Hypertension (PAH)
Ticker(s): MRKInstitution: National Jewish Health
- Director of clinical cardiology at National Jewish Health, associate professor of clinical practice and the university of Colorado, and fellow of the American college of cardiology.
- Currently manages ~100 patients with pulmonary arterial hypertension.
- Research interests include cardiac sarcoid, public health, exercise and health outcomes, and cardiac nutrition.
How many PAH patients do you treat?
Added By: sara_adminHow has your experience with Winrevair been?
Added By: sara_adminDo you anticipate your prescribing patterns to increase, stay the same, or decrease?
Added By: sara_adminWhat is your high level opinion of the recent Sotatercept data?
Added By: ben_adminRank your excitement level for the new data on Sotatercept on a scale of 1-10
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
